The prognostic significance of low-frequency somatic mutations in metastatic cutaneous melanoma
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
Zhao, X, et al. The Prognostic Significance of Low-frequency Somatic Mutations In Metastatic Cutaneous Melanoma. Frontiers Media S.A., 2019. https://doi.org/10.17615/n84y-5q28APA
Zhao, X., Little, P., Hoyle, A., Pegna, G., Hayward, M., Ivanova, A., Parker, J., Marron, D., Soloway, M., Jo, H., Salazar, A., Papakonstantinou, M., Bouchard, D., Jefferys, S., Hoadley, K., Ollila, D., Frank, J., Thomas, N., Googe, P., Ezzell, A., Collichio, F., Lee, C., Earp, H., Sharpless, N., Hugo, W., Wilmott, J., Quek, C., Waddell, N., Johansson, P., Thompson, J., Hayward, N., Mann, G., Lo, R., Johnson, D., Scolyer, R., Hayes, D., & Moschos, S. (2019). The prognostic significance of low-frequency somatic mutations in metastatic cutaneous melanoma. Frontiers Media S.A. https://doi.org/10.17615/n84y-5q28Chicago
Zhao, X., P Little, A.P Hoyle, G.J Pegna, M.C Hayward, A Ivanova, J.S Parker et al. 2019. The Prognostic Significance of Low-Frequency Somatic Mutations In Metastatic Cutaneous Melanoma. Frontiers Media S.A.. https://doi.org/10.17615/n84y-5q28- Creator
-
Zhao, X.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Little, P.
- Affiliation: Gillings School of Global Public Health, Department of Biostatistics
-
Hoyle, A.P.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Pegna, G.J.
- Affiliation: School of Medicine, Division of Hematology/Oncology
-
Hayward, M.C.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Ivanova, A.
- Affiliation: Gillings School of Global Public Health, Department of Biostatistics
-
Parker, J.S.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Marron, D.L.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Soloway, M.G.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Jo, H.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Salazar, A.H.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Papakonstantinou, M.P.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Bouchard, D.M.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Jefferys, S.R.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Hoadley, K.A.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Ollila, D.W.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Frank, J.S.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Thomas, N.E.
- Affiliation: School of Medicine, Department of Dermatology
-
Googe, P.B.
- Affiliation: School of Medicine, Department of Dermatology
-
Ezzell, A.J.
- Affiliation: School of Medicine, Department of Cell Biology and Physiology
-
Collichio, F.A.
- Affiliation: School of Medicine, Division of Hematology/Oncology
-
Lee, C.B.
- Affiliation: School of Medicine, Division of Hematology/Oncology
-
Earp, H.S.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Sharpless, N.E.
- Affiliation: N.C. Cancer Hospital, UNC Lineberger Comprehensive Cancer Center
-
Hugo, W.
- Other Affiliation: University of California, Los Angeles
-
Wilmott, J.S.
- Other Affiliation: University of Sydney
-
Quek, C.
- Other Affiliation: University of Sydney
-
Waddell, N.
- Other Affiliation: Queensland Institute of Medical Research
-
Johansson, P.A.
- Other Affiliation: Queensland Institute of Medical Research
-
Thompson, J.F.
- Other Affiliation: University of Sydney
-
Hayward, N.K.
- Other Affiliation: Queensland Institute of Medical Research
-
Mann, G.J.
- Other Affiliation: University of Sydney
-
Lo, R.S.
- Other Affiliation: University of California, Los Angeles
-
Johnson, D.B.
- Other Affiliation: Vanderbilt-Ingram Cancer Center
-
Scolyer, R.A.
- Other Affiliation: Queensland Institute of Medical Research
-
Hayes, D.N.
- Affiliation: School of Medicine, Division of Hematology/Oncology
-
Moschos, S.J.
- Affiliation: School of Medicine, Division of Hematology/Oncology
- Abstract
- Background: Little is known about the prognostic significance of somatically mutated genes in metastatic melanoma (MM). We have employed a combined clinical and bioinformatics approach on tumor samples from cutaneous melanoma (SKCM) as part of The Cancer Genome Atlas project (TCGA) to identify mutated genes with potential clinical relevance. Methods: After limiting our DNA sequencing analysis to MM samples (n = 356) and to the CANCER CENSUS gene list, we filtered out mutations with low functional significance (snpEFF). We performed Cox analysis on 53 genes that were mutated in ≥3% of samples, and had ≥50% difference in incidence of mutations in deceased subjects versus alive subjects. Results: Four genes were potentially prognostic [RAC1, FGFR1, CARD11, CIITA; false discovery rate (FDR) < 0.2]. We identified 18 additional genes (e.g., SPEN, PDGFRB, GNAS, MAP2K1, EGFR, TSC2) that were less likely to have prognostic value (FDR < 0.4). Most somatic mutations in these 22 genes were infrequent (< 10%), associated with high somatic mutation burden, and were evenly distributed across all exons, except for RAC1 and MAP2K1. Mutations in only 9 of these 22 genes were also identified by RNA sequencing in >75% of the samples that exhibited corresponding DNA mutations. The low frequency, UV signature type and RNA expression of the 22 genes in MM samples were confirmed in a separate multi-institution validation cohort (n = 413). An underpowered analysis within a subset of this validation cohort with available patient follow-up (n = 224) showed that somatic mutations in SPEN and RAC1 reached borderline prognostic significance [log-rank favorable (p = 0.09) and adverse (p = 0.07), respectively]. Somatic mutations in SPEN, and to a lesser extent RAC1, were not associated with definite gene copy number or RNA expression alterations. High (>2+) nuclear plus cytoplasmic expression intensity for SPEN was associated with longer melanoma-specific overall survival (OS) compared to lower (≤ 2+) nuclear intensity (p = 0.048). We conclude that expressed somatic mutations in infrequently mutated genes beyond the well-characterized ones (e.g., BRAF, RAS, CDKN2A, PTEN, TP53), such as RAC1 and SPEN, may have prognostic significance in MM.
- Date of publication
- 2019
- Keyword
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- License
- Attribution 3.0 United States
- Journal title
- Frontiers in Oncology
- Journal volume
- 9
- Journal issue
- JAN
- ISSN
- 2234-943X
- Publisher
- Frontiers Media S.A.
Relations
- Parents:
- In Collection:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
fonc-08-00584.pdf | 2021-02-19 | Public | Download |